How is Longevity Redefining Healthy Aging?

As advances in medicine, biotechnology, and public health continue to extend life expectancy, the conversation around aging is shifting. The focus is increasingly moving beyond simply living longer toward helping people remain healthier, more active, and more independent for longer. Yet lifespan is only part of the equation. Equally important is health span, or the number of years lived in good health, free from significant disease or disability.

While life expectancy has risen dramatically over the past century, many individuals still spend a substantial portion of later life managing chronic illness and age-related conditions. This divide between lifespan and health span has become a key challenge for healthcare systems and a major focus for researchers, companies, and investors.

In response, a new frontier of innovation is emerging across medicine and biotechnology, from obesity treatment and personalized medicine to therapies targeting inflammation, metabolic dysfunction, and the biological drivers of aging. Below are several examples of these emerging areas of innovation.

The Gap Between Lifespan and Health Span:

The gap between lifespan and health span remains significant. Globally, individuals spend nearly a decade of their lives in poorer health, managing disease or disability. Research suggests this gap has widened over the past two decades, highlighting an important challenge for healthcare systems and aging populations alike.

The United States experiences one of the largest gaps, with Americans spending an estimated 12.4 years in less-than-optimal health later in life, compared with a global average of approximately 9.2 years. The goal of healthy aging is not simply to extend life, but to increase the number of years lived independently, actively, and in good health.

Scientific Advancements Focused on Health Span:

Several emerging areas of biotechnology are seeking to address the biological drivers of aging:

The Next Generation of GLP-1 Innovation:

GLP-1 therapies such as Wegovy and Zepbound were originally developed to treat diabetes but have since transformed the treatment of obesity. By helping patients achieve and maintain healthier body weight, these therapies may indirectly support healthy aging by reducing the risk of conditions such as cardiovascular disease, kidney disease, liver disease, osteoarthritis, sleep disorders, and other obesity-related complications.

Researchers are also investigating whether GLP-1 therapies may have benefits beyond weight management, including potential applications in neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease. While study results have been mixed and no definitive benefits have yet been established, the field continues to attract significant scientific interest.

Although current obesity therapies have produced impressive weight-loss outcomes, several challenges remain. Many patients discontinue treatment, regain weight over time, or experience meaningful reductions in lean muscle mass. As a result, pharmaceutical companies including Eli Lilly and Novo Nordisk are increasingly focused on developing therapies that can:

For long-term weight maintenance, companies such as Amgen and Viking Therapeutics are pursuing promising next-generation therapies. Amgen is developing treatments that may eventually support dosing every two to three months, a significant improvement over current weekly injection schedules.

Viking Therapeutics is also generating interest with VK2735, which is being developed in both injectable and oral formulations. This flexibility may offer patients more personalized treatment options and support long-term adherence. Early clinical data have demonstrated meaningful weight-loss benefits alongside improvements in inflammatory markers, blood pressure, and prediabetes measures.

Prevention, Early Detection, and Healthy Aging:

Ultimately, healthy aging begins long before disease develops. Advances in diagnostic testing, biomarker analysis, and preventive screening may allow healthcare providers to identify risks earlier and intervene before symptoms emerge.

At the same time, many of the most powerful drivers of healthy aging remain accessible and well-established. Regular physical activity, quality sleep, balanced nutrition, and ongoing social engagement continue to play a critical role in maintaining both physical and cognitive health.

Social connection, in particular, has emerged as an important factor in healthy aging. Research has linked social isolation to increased risks of cognitive decline, cardiovascular disease, and mortality. Hearing health is also receiving greater attention, as untreated hearing loss can reduce social engagement and may contribute to cognitive deterioration over time.

Looking Ahead:

As healthcare increasingly shifts from treating disease to preventing it, healthy aging represents one of the most promising areas of medical innovation. Advances in obesity treatment, personalized medicine, diagnostics, and age-related therapeutics have the potential to help individuals not only live longer, but live healthier and more fulfilling lives.

To learn more about the science and investment opportunities surrounding healthy aging and longevity, tune in to the latest episode of Let's Talk Future, The Next Wave of Healthy Aging, where Jane Ross sits down with Jay Olson, CFA, Managing Director and Senior Analyst covering Biotechnology at Oppenheimer. Together, they explore the innovations shaping the future of healthy aging and the companies driving progress across the biotechnology landscape.

Key Takeaways

Reach out to an Oppenheimer Financial Professional today for guidance and insights tailored to your individual goals.